Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma

Paola Neri, MD, PhD, Peter Duggan, MD, FRCPC, Kathy Gratton, Li Ren, PhD, Douglas A. Stewart, MD, FRCP, Jonathan J Keats, PhD, Nizar J. Bahlis, MD

Blood (2013) 122 (21): 1978.

https://doi.org/10.1182/blood.V122.21.1978.1978

Published: 2013

Journal Articles

Presence of Minimal Residual Disease by Flow Cytometry After Induction Chemotherapy Is Less Predictive of Overall and Progression-Free Survival Compared to Conventional Prognostic Factors Including Cytogenetic Risk and Age

Cameron D. Griffiths, MD, Elena Liew, MD, Jennifer K. Grossman, MD, BSc, Douglas A. Stewart, MD, FRCP, Joanne Luider, Iwona Auer, Adnan Mansoor, MD, FRCPC, Michelle Geddes, MD

Blood (2012) 120 (21): 1424.

https://doi.org/10.1182/blood.V120.21.1424.1424

Published: 2012

Journal Articles

Role of Mir-30e in Multiple Myeloma Cells Resistance to Lenalidomide and Bortezomib

Paola Neri, MD, PhD, Kathy Gratton, Li Ren, PhD, Jordan Johnson, Jiri Slaby, MD, Peter Duggan, MD, Douglas A. Stewart, MD, FRCP, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 323.

https://doi.org/10.1182/blood.V120.21.323.323

Published: 2012

Journal Articles

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

Paola Neri, MD, PhD, Peter Duggan, MD, FRCPC, Kathy Gratton, Li Ren, PhD, Jordan Johnson, Jiri Slaby, MD, Douglas A. Stewart, MD, FRCP, Jonathan J Keats, PhD, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 1862.

https://doi.org/10.1182/blood.V120.21.1862.1862

Published: 2012

Journal Articles

Lenalidomide Suppresses 5′-Cap-Independent C-MYC Translation in Multiple Myeloma Cells

Jiri Slaby, MD, Jordan Johnson, Paola Neri, MD, PhD, K Gratton, Li Ren, PhD, Douglas A. Stewart, MD, FRCP, Peter Duggan, MD, FRCPC, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 3943.

https://doi.org/10.1182/blood.V120.21.3943.3943

Published: 2012

Journal Articles

A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

Paola Neri, MD, PhD, Andrew R Belch, MD, Jordan Johnson, Kathy J Gratton, Li Ren, PhD, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD

Blood (2011) 118 (21): 987.

https://doi.org/10.1182/blood.V118.21.987.987

Published: 2011

Journal Articles

Mir-34a Sensitizes Multiple Myeloma (MM) Cells to the Proteasome Inhibitor Bortezomib

Erin Stebner, Paola Neri, MD, PhD, Jordan Johnson, Kathy J Gratton, Li Ren, PhD, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD

Blood (2011) 118 (21): 138.

https://doi.org/10.1182/blood.V118.21.138.138

Published: 2011

Journal Articles

Bortezomib Impairs Myeloma Cells (MM) Homologous Recombination Through Inhibition of the E2-Ubiquitin-Conjugating Enzyme UBC13

Paola Neri, MD, PhD, Li Ren, PhD, Jordan Johnson, Kathy J Gratton, Erin Stebner, Carolyn J Owen, MD, FRCPC, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD

Blood (2011) 118 (21): 1834.

https://doi.org/10.1182/blood.V118.21.1834.1834

Published: 2011

Journal Articles

Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors

Paola Neri, MD, PhD, Li Ren, PhD, Kathy Gratton, Erin Stebner, Carolyn J Owen, MD, FRCPC, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar J Bahlis, MD

Blood (2010) 116 (21): 789.

https://doi.org/10.1182/blood.V116.21.789.789

Published: 2010

Journal Articles

Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) 0–1 Scores Predict Improved Outcome

Anthea Peters, MD, MSc, FRCPC, James A Russell, MD, Andrew Daly, MD, FRCPC, Nizar J Bahlis, MD, Michelle Geddes, MD, Peter Duggan, MD, FRCPC, Mary Lynn Savoie, MD, FRCPC, Douglas A. Stewart, MD, FRCP

Blood (2010) 116 (21): 687.

https://doi.org/10.1182/blood.V116.21.687.687

Published: 2010

Journal Articles

A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma

Nizar J Bahlis, MD, Carolyn J Owen, MD, FRCPC, Paola Neri, MD, PhD, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Kathy J Gratton, Peter Duggan, MD, FRCPC, Pietro Ravani, MD, PhD, Douglas A. Stewart, MD, FRCP

Blood (2010) 116 (21): 324.

https://doi.org/10.1182/blood.V116.21.324.324

Published: 2010

Journal Articles

Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

Carolyn J Owen, MD, FRCPC, Andrew Daly, MD, FRCPC, Neil Chua, MD, FRCPC, Douglas A. Stewart, MD, FRCP

Blood (2010) 116 (21): 1346.

https://doi.org/10.1182/blood.V116.21.1346.1346

Published: 2010

Journal Articles

Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496

Ranjana Advani, MD, Fangxin Hong, PhD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Sue Robinson, MD, Randy D. Gascoyne, MD, Henry Wagner, MD, Patrick J Stiff, MD, Bruce D. Cheson, MD, Douglas A. Stewart, MD, FRCP, Leo I Gordon, MD, FACP, Brad Kahl, MD, Jonathan W. Friedberg, MD, Kristie A. Blum, MD, Thomas M. Habermann, MD, Joseph Tuscano, MD, Richard Hoppe, MD, Sandra J. Horning, MD

Blood (2010) 116 (21): 416.

https://doi.org/10.1182/blood.V116.21.416.416

Published: 2010

NARROW

Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma

Presence of Minimal Residual Disease by Flow Cytometry After Induction Chemotherapy Is Less Predictive of Overall and Progression-Free Survival Compared to Conventional Prognostic Factors Including Cytogenetic Risk and Age

Role of Mir-30e in Multiple Myeloma Cells Resistance to Lenalidomide and Bortezomib

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

Lenalidomide Suppresses 5′-Cap-Independent C-MYC Translation in Multiple Myeloma Cells

A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

Mir-34a Sensitizes Multiple Myeloma (MM) Cells to the Proteasome Inhibitor Bortezomib

Bortezomib Impairs Myeloma Cells (MM) Homologous Recombination Through Inhibition of the E2-Ubiquitin-Conjugating Enzyme UBC13

Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors

Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) 0–1 Scores Predict Improved Outcome

A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma

Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only